A retrospective comparison was carried out on adult patients receiving HLA-identical allogeneic haemopoietic stem cell transplants from siblings in Australia in 1996, comparing bone marrow with G-CSF-mobilised peripheral blood stem cells. A total of 131 transplant recipients from nine centres were included in this study, of whom 79 received bone marrow, 44 blood stem cells and eight both. All but three of the 131 patients had cyclosporin and methotrexate as graftversus-host disease prophylaxis. The minimum follow-up time for surviving patients is 27 months. Comparisons were carried out between the BM and PBSC groups. There were no significant differences between groups in age, sex, diagnosis, donor characteristics or pretransplant conditioning. Median time to neutrophil recovery of 0.5 × 10 9 /l was 14 days for PBSC recipients, compared to 19 days for marrow recipients (P Ͻ 0.0005). Median time to platelet recovery of 20 × 10 9 /l was 17 days for PBSC recipients, compared to 28 days for marrow recipients (P Ͻ 0.0005). There were no significantly increased risks of either acute or chronic GVHD in the PBSC recipients. There were no significant differences between the groups in the incidence of major transplant-related complications, disease-free survival or overall survival. Bone Marrow Transplantation (2001) 28, 21-27.
faster engraftment times, as well as dispensing with the need for donors to undergo bone marrow harvests under general anaesthetic.
The use of growth factor-mobilised donor PBSC in allogeneic haemopoietic cell transplantation as compared to bone marrow is attractive not only because it avoids exposure of the donor to general anaesthetic during bone marrow harvest, 2, 3 but also because initial data suggest faster engraftment for the recipient. [4] [5] [6] [7] [8] Growth factormobilised harvests are known to differ significantly in their composition compared with bone marrow harvests, particularly with respect to T cell (1 log increase) and NK cell (20-fold increase) numbers. 2, 3 There are concerns that this level of cell dose in a graft might cause an increased incidence of graft-versus-host disease in recipients. There are also concerns that administering growth factor to healthy donors may have adverse longterm effects; 9 due to the large numbers and long followup needed, at this point no studies have produced conclusive findings on this subject.
Several recent overseas studies have now shown that allogeneic PBSC transplants result in equal or shorter engraftment times than do allogeneic bone marrow transplants with no measurable increase in the incidence of graft-versus-host disease. [5] [6] [7] [8] However, length of followup is a concern with these studies, as the evaluation of chronic GVHD requires at least 1 year of follow-up post transplant. A recent retrospective study indicated that allogeneic PBSC transplants may be associated with increased risk of chronic GVHD. 10 However, preliminary results from the recent EBMT randomised prospective trial did not show significant evidence of this. 11 The aim of this multi-centre retrospective comparison study was to investigate the safety of growth factor-mobilised allogeneic PBSC transplants by comparing patients undergoing the procedure in Australia in 1996 with patients who had allogeneic bone marrow transplants during the same year.
Bone Marrow Transplantation

Patients and methods
Patient and donor details
Patients were selected for this study from data kept by the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), which records more than 95% of haemopoietic cell transplants carried out each year in Australia, and is thus an unbiased data source. From a total of 289 allogeneic transplants carried out in Australia in 1996, 131 were selected who had HLA-A, -B, -DR-identical sibling donors, were aged between 17 and 58 years, and were receiving their first allogeneic transplant. Nine Australian hospitals were involved in this study.
Follow-up information was sought from the centres up to 31 March 1999 which is the closing date for this study. Thus, the minimum follow-up time for surviving patients is 27 months.
Patients were separated into groups according to cell source: bone marrow, peripheral blood stem cells or a combination of both.
The study was restricted to the calendar year of 1996 to have as uniform a group as possible and to provide relatively long follow-up for all patients in the study.
Statistical methodology
Patients were considered as evaluable for engraftment and GVHD incidence if they survived at least 21 days after BMT.
Grading of graft-versus-host disease was carried out according to IBMTR definitions. 12 Graft-versus-host disease was classified as acute when occurring up to day 100 post transplant, and chronic after this time. Classification of major adverse events and causes of death were taken from IBMTR definitions. 12 Haemorrhage refers to any bleeding event apart from bruising or haemorrhagic cystitis.
Differences between groups for matching parameters were assessed using either a Mann-Whitney U-test (patient age, donor age, female donor parity, number of methotrexate doses), or Fisher's exact test (patient sex, donor sex, donor-recipient sex match, diagnosis, conditioning regimen).
Differences between groups for proportion of evaluable patients who engrafted were assessed using Fisher's exact test. Differences between groups for engraftment parameters were assessed using a Mann-Whitney U-test. Overall survival and the incidence of graft-versus-host disease were calculated using Kaplan-Meier product limit estimates, 13 and differences between groups were assessed with the log-rank test. Differences between groups in incidence of GVHD in specific organs were assessed using Fisher's exact test.
The significance of relevant factors on survival and GVHD incidence was assessed using Cox regression analysis.
Results
Matching of the two groups
The final group of study patients comprised 79 bone marrow recipients and 44 peripheral blood recipients. An additional eight patients received both marrow and PBSC. Six out of these eight patients were in the experimental arm of the Royal Melbourne Study of BM vs BM + PBSC, 14 and the two others had both marrow and PBSC infused because PBSC collection had not yielded sufficient numbers of cells. For these reasons, all eight were excluded from the analysis as they were not comparable with either of the groups.
Bone marrow and peripheral blood patient groups were well matched in terms of patient age, donor age, patient and donor sex, donor-recipient sex matching, diagnosis and prognosis (Table 1 ). There were no statistically significant differences between the groups in any of these parameters.
Length of follow-up
At the closing point for this study (end of March 1999), the median follow-up time for live patients in the bone marrow group was 981 days or 2.7 years (minimum 841 days, maximum 1181 days) and the median follow-up time for live patients in the peripheral blood group was 1010 days or 2.8 years (minimum 840 days, maximum 1148 days).
Outcome of transplant
In the bone marrow group, two patients died too early to be evaluable for engraftment (day 5 and 16 post transplant), and 74 of 77 evaluable patients had sustained engraftment (96%). Of those bone marrow recipients who did not engraft, two died from persistent disease at day 62 and 137 post transplant, and one is alive with persistent disease. In the peripheral blood group, three patients died too early to be evaluable for engraftment (day 11, 13 and 21 post transplant), and 37 of 41 patients had sustained engraftment (90%). Of those peripheral blood recipients who did not engraft, two had partial engraftment, but died on day 32 and 33 post transplant with bacterial infection and haemorrhage, and two died with persistent disease at day 86 and 90 post transplant. The difference between the groups for the proportion of evaluable patients who engrafted was not statistically significant (P = 0.2).
Rates of engraftment
Time to engraftment was evaluated for several events: number of days to 0.5 × 10 9 neutrophils per litre, days to 1.0 × 10 9 neutrophils, days to 20 × 10 9 platelets and days to 50 × 10 9 platelets. Peripheral blood recipients attained neutrophil recovery to 0.5 × 10 9 on average 5 days faster than bone marrow recipients, and platelet recovery to 20 × 10 9 on average 11 days faster. Differences were strongly statistically significant for all of these measures ( Table 2 ). The peripheral blood group also had a significantly shorter average length of first stay in hospital (P = 0.04). 
Adverse events post transplant
The incidence of major adverse events post transplant was similar between the two groups with no significant differences ( Table 3) .
Incidence of acute graft-versus-host disease
The actuarial incidence of acute graft-versus-host disease at day 100 post transplant was 74% for bone marrow recipients and 73% for peripheral blood recipients. The actuarial incidence of acute GVHD of grade II or higher at day 100 post transplant was 44% in peripheral blood recipients and 39% in bone marrow recipients (Figure 2 ). The peripheral Bone Marrow Transplantation blood group showed a much more rapid acquisition of acute GVHD grade II or higher, with actuarial probability of 31% at day 30 compared with 18% for the bone marrow group. However, differences between groups were not significant. The incidence of acute GVHD in specific organs was similar between evaluable patients in the two groups (Table 4) . Acute GVHD of the liver was significantly higher for bone marrow recipients (41% compared to 22% for peripheral blood recipients, P = 0.05), but this differ-Bone Marrow Transplantation Difference between groups not significant (P = 0.3) Figure 2 Overall survival probability. ence was not significant for hepatic GVHD grade II or higher (24% compared to 16% for peripheral blood recipients, P = 0.3). Cox multivariate analysis was carried out to determine the significant factors affecting development of acute GVHD grade II or higher. Factors tested were age, sex, stem cell source, whether poor risk (ie all other than acute leukaemia in first remission or CML in first chronic phase) and conditioning regimen. A reduced multivariate model was produced using backward stepwise conditional selection. The only significant factor for grade II+ GVHD in the reduced multivariate model was age (age 35+ years, P = 0.01). Source of stem cells was not a significant factor.
Incidence of chronic graft-versus-host disease
The actuarial incidence of chronic GVHD at the time of the study end was 80% for the peripheral blood group and 63% for the bone marrow group. The difference between the two groups was not significant (P = 0.7). The actuarial incidence of extensive chronic GVHD at the time of the study end was 66% for the peripheral blood group and 60% for the bone marrow group. The difference between the two groups was not significant (P = 0.8).
The incidence of chronic GVHD in specific organs differed between bone marrow and PBSC recipients, but none of the differences was significant. The incidence of chronic GVHD of the skin was higher among bone marrow recipients (67% of all patients who had cGVHD) than peripheral blood recipients (58%). The incidence of chronic GVHD of the liver was higher among peripheral blood recipients (67% of all patients who had cGVHD) than bone marrow recipients (50%), as was the incidence of chronic GVHD of the mouth (50% vs 39%) and chronic pulmonary GVHD (13% vs 3%, Table 5 ).
The incidence of de novo chronic GVHD (ie chronic GVHD without preceding acute GVHD) was four out of 24 patients with cGVHD in the peripheral blood group (17%) and nine out of 36 patients with cGVHD in the bone marrow group (25%).
Survival at 100 days post transplant
Overall survival probability at 100 days post transplant was 79% for the bone marrow group and 68% for the peripheral blood group. Multivariate Cox regression analysis of survival at day 100 showed that high-risk disease (ie acute leukaemia past first remission and CML past first chronic phase) was a significant risk factor for early death post transplant (P = 0.03), but blood stem cells as a graft source was not (P = 0.2).
Among the recipients with high-risk disease, there was no significant difference in early mortality between the peripheral blood and marrow groups (P = 0.5, Kaplan-Meier log-rank test), but the two groups were small (PBSC, 30; marrow, 47).
Overall survival and disease-free survival
Overall survival probability at 2.5 years post transplant was 50% for the bone marrow group and 39% for the peripheral blood group. The difference between groups was not significant (Figure 3 ). Disease-free survival probability at 2.5 years post transplant was 44% for the bone marrow group and 34% for the peripheral blood group. Again the difference between groups was not significant. At the time of study end, there were two subjects in the peripheral blood group and six in the bone marrow group who had relapsed and were alive.
Cox multivariate regression was carried out to determine the significant pretransplant factors affecting overall survival. Factors tested were age, sex, stem cell source, Table 5 Incidence of clinical chronic GVHD at 101 days post transplant in specific organs for patients who had cGVHD whether poor risk (ie all other than acute leukaemia in first remission or CML in first chronic phase) and conditioning regimen. The only significant risk factor for overall survival in the reduced multivariate model was poor risk status (P = 0.03). Source of stem cells was not a significant factor.
Causes of death
There were 66 deaths in 123 patients in the two groups up to the study cut-off time. The main causes of death in the bone marrow group were relapse (n = 9), pneumonia or interstitial pneumonitis (n = 8) and graft-versus-host disease (n = 6). The main causes of death in the peripheral blood group were organ damage or failure (n = 7), graftversus-host disease (n = 7) and relapse (n = 5). Differences between the two groups in the distribution of causes of death were not significant (Table 6 ).
Discussion
It is now well established that allogeneic transplants utilising peripheral blood stem cells result in more rapid engraftment compared to those using bone marrow.
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Russell et al, 5 Bensinger et al, 6 Urbano-Ispizua et al 8 and our study found significant or near-significant acceleration in both neutrophil and platelet engraftment. This translated into significantly fewer platelet transfusions in the two former studies and reduced hospital stay in Russell's study subjects and this study. Several other recent studies with smaller numbers of patients have also found equivalent or faster engraftment for adult patients, 15, 16 paediatric patients, 17 and using paediatric donors. 18 Ottinger et al 19 found improved immune reconstitution with allotransplantation of peripheral blood stem cells instead of bone marrow. Although stem cell transplants involve the infusion of larger cell numbers than bone marrow transplants, the incidence of acute graft-versus-host disease was not shown to be higher for stem cell transplants in any of these studies. [5] [6] [7] [8] [9] [10] [20] [21] [22] [23] [24] [25] [26] [27] [28] The incidence of chronic GVHD is more difficult to evaluate as it requires longer follow-up times. While several studies have shown higher incidence of chronic GVHD in stem cell recipients, this finding has not been universal. [23] [24] [25] [26] [27] [28] In studies that have been carried out, the incidence of chronic GVHD varies from 21% to 87% in different groups. 9, 10, [20] [21] [22] [23] [24] [25] [26] [27] [28] Previous reports 10, [20] [21] [22] have found indications of increased chronic GVHD in allogeneic peripheral blood transplants. Several recent studies with sample sizes of between 12 and 50 subjects have found significant or near-significant increases in the incidence of chronic GVHD in peripheral blood recipients compared to matched bone marrow controls. [24] [25] [26] [27] [28] However, a presentation by Paveletic et al 23 describing a group with comparable numbers to this study, did not find significant differences.
A recent study by Bacigalupo et al 29 found that the shortterm outcomes of 45 allogeneic peripheral blood transplants were not significantly different from matched bone marrow transplant controls. In another recent prospective study, Mahmoud et al 30 found faster engraftment in 15 peripheral blood recipients and a lower incidence of acute GVHD compared to bone marrow controls. A large multi-centre prospective randomised trial involving 138 patients in centres in California and Washington found improved engraftment in peripheral blood recipients, no significant differences in acute or chronic GVHD, and improved survival in peripheral blood recipients. 31 However a large prospective trial involving 101 recipients with early stage leukaemia reported faster engraftment, but higher occurrence of chronic GVHD for peripheral blood recipients. 32 The inferences from this retrospective non-matched study are that allogeneic peripheral blood stem cell transplants in adult matched siblings result in more rapid engraftment with equivalent safety to comparable bone marrow transplants. The incidence of acute and chronic GVHD were not seen to be significantly elevated for peripheral blood recipients in this study. Overall survival and disease-free survival were also not significantly different between groups. The incidence of haemorrhage was high (34 patients in the two groups), but this does include all major and minor bleeding events. Overall survival probability at 2.5 years was higher for bone marrow (50%) than PBSC recipients (39%), although this difference was not significant. This difference is due to a number of deaths in the PBSC group between 1 and 1.5 years post transplant from late complications and GVHD.
Our study did not involve matched controls and there is thus a possibility that the groups are not comparable. However, the criteria for inclusion were set to capture a reasonably similar set of patients -adults with HLA-identical sibling donors having first transplants during 1996. There were no significant differences between the groups in the demographic and disease-related variables tested, and no reason to suspect that there was an imbalance in any other nontested variable.
It is relevant to compare the results of the recent combined IBMTR and EBMT retrospective study 33 with this study. The IBMTR/EBMT study had a very similar meth-odology to this study, but with much larger sample size (n = 824). The authors found a significant elevation in chronic GVHD incidence in peripheral blood stem cell recipients compared to recipients of bone marrow (65% vs 53%, P = 0.02). This result indicates that the difference in chronic GVHD in our study may have become statistically significant if there were a larger number of subjects and thus increased statistical power.
The IBMTR/EBMT retrospective study found that for recipients with high-risk acute leukaemia, there was significantly lower treatment-related mortality in PBSC recipients compared to marrow (P = 0.04). This was also found for CML patients (P = 0.004). Our study did not find significant differences in treatment-related mortality for highrisk subjects, but the comparison was done for all disease types combined.
Recent results from the EBMT randomised prospective study comparing allogeneic transplantation of PBSC with bone marrow showed significantly elevated incidence of acute GVHD in PBSC recipients (52% vs 39%). There was also a significantly elevated incidence of chronic GVHD in PBSC recipients (74% vs 53%) but no significant differences in GVHD-associated mortality or overall survival. 34 The general lack of serious complications and mortality due to increased levels of GVHD despite the infusion of 1 log greater numbers of T cells and 20-fold greater numbers of NK cells compared to a bone marrow graft has been noted 2 and several possible explanations have been put forward including the effect of G-CSF on T helper subset function, 35 the suppression of GVHD but maintenance of a graft-versus-leukaemia effect through a perforin-dependent pathway, 36 the capacity of mononuclear cells to induce GVHD 37 and the effect of co-existing monocytes in the peripheral blood stem cell collection on T and NK cell function. 38 The most recent results from large studies indicate that there is an increased acute and chronic GVHD risk associated with blood stem cell transplants, but large numbers are needed to evaluate this precisely and show significance. Many studies carried out on this topic, including our study and the EBMT prospective randomised trial, have indicated that while the incidence of some transplant-related complications differs between allogeneic bone marrow and PBSC recipients, overall survival probability has not been shown to be significantly different.
